Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash from Investing Activities: 2017-2025

Historic Cash from Investing Activities for Dianthus Therapeutics (DNTH) over the last 6 years, with Sep 2025 value amounting to -$201.3 million.

  • Dianthus Therapeutics' Cash from Investing Activities rose 22.40% to -$201.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$183.1 million, marking a year-over-year increase of 32.65%. This contributed to the annual value of -$286.8 million for FY2024, which is 1516.15% down from last year.
  • Dianthus Therapeutics' Cash from Investing Activities amounted to -$201.3 million in Q3 2025, which was down 861.11% from $26.4 million recorded in Q2 2025.
  • Dianthus Therapeutics' Cash from Investing Activities' 5-year high stood at $26.4 million during Q2 2025, with a 5-year trough of -$259.4 million in Q3 2024.
  • For the 3-year period, Dianthus Therapeutics' Cash from Investing Activities averaged around -$38.8 million, with its median value being -$5.5 million (2024).
  • As far as peak fluctuations go, Dianthus Therapeutics' Cash from Investing Activities surged by 17,048.84% in 2023, and later tumbled by 2,154.36% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Cash from Investing Activities (Quarterly) stood at -$12.7 million in 2022, then spiked by 34.96% to -$8.2 million in 2023, then tumbled by 180.56% to -$23.1 million in 2024, then increased by 22.40% to -$201.3 million in 2025.
  • Its last three reported values are -$201.3 million in Q3 2025, $26.4 million for Q2 2025, and $14.8 million during Q1 2025.